Clinical trial
GTI-2040, Docetaxel, and Prednisone in Treating Patients With Prostate Cancer
NCT00087165 · University Health Network, Toronto, Other · Completed
Key facts
| NCT number | NCT00087165 |
|---|---|
| Title | GTI-2040, Docetaxel, and Prednisone in Treating Patients With Prostate Cancer |
| Official title | A Phase II Study of GTI-2040 in Combination With Docetaxel and Prednisone in Hormone-Refractory Prostate Cancer |
| Lead sponsor | University Health Network, Toronto, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Prostate Cancer |
| Intervention type | Biological, Drug |
| Interventions | GTI-2040, docetaxel, prednisone |
| Enrollment | 22 |
| Start date | Jan 1, 2005 |
| Primary completion | Sep 1, 2006 |
| Completion | Dec 1, 2006 |
| First posted | Jul 12, 2004 |
| Last update posted | Apr 28, 2021 |
| Countries | Canada |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: